Company profile · Sponsor
Beone
Beone Medicines Ireland Limited
- Pipeline
- 24
- Drugs
- 3
- Patents
- 0
Quick answer
Beone (ONC) is a pharma company. headquartered in BASEL, GB. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 3 drugs, and 0 patents to this profile..
Company facts
Pipeline (24)
Search pipeline →-
BGB-11417, BGB-11417 placebo, BGB-11417, BGB-11417, BGB-11417, Zanubrutinib
Beone
relapsed or refractory mantle cell lymphoma (R/R MCL)
1 trial -
BGB-11417, Zanubrutinib, BGB-11417, Venclyxto 100 mg film-coated tablets, Gazyvaro 1,000 mg concentrate for solution for infusion., BGB-11417, BGB-11417
Beone
Previously Untreated Chronic Lymphocytic Leukemia
1 trial -
BGB-16673
Beone
CLL
1 trial -
BGB-16673
Beone
Chronic Lymphocytic Leukemia
2 trials -
BGB-43395
Beone
HR+/HER2- Breast Cancer
1 trial -
Jaypirca 100 mg film-coated tablets, BGB-16673, BGB-16673
Beone
Chronic lymphocytic leukemia (CLL), Small lymphocytic lymphoma (SLL)
1 trial -
Ociperlimab, Ociperlimab, Pamiparib, Pamiparib, Tislelizumab
Beone
Solid tumors and hamatological malignancies
1 trial -
Pamiparib capsule
Beone
Ovarian Cancer
1 trial -
Sonrotoclax
Beone
Mantle Cell Lymphoma
1 trial -
Sonrotoclax
Beone
CLL
1 trial -
Sonrotoclax
Beone
Chronic Lymphocytic Leukemia
4 trials -
Subcutaneous Tislelizumab
Beone
Metastatic Gastric Adenocarcinoma
1 trial -
Tislelizumab
Beone
Urothelial Carcinoma
1 trial -
Tislelizumab
Beone
Non Small Cell Lung Cancer
4 trials -
Tislelizumab
Beone
Classical Hodgkin Lymphoma
1 trial -
Tislelizumab
Beone
Esophageal Squamous Cell Carcinoma (ESCC)
1 trial -
Tislelizumab
Beone
Advanced Malignancies
1 trial -
Tislelizumab 300 mg solution for injection, Tevimbra 100 mg concentrate for solution for infusion
Beone
Locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
1 trial -
Venclyxto 10 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, BGB-11417, MabThera 100 mg concentrate for solution for infusion, BGB-11417, BGB-11417, Gazyvaro 1,000 mg concentrate for solution for infusion., BGB-11417, MabThera 500 mg concentrate for solution for infusion, Venclyxto 50 mg film-coated tablets
Beone
Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
1 trial -
Venclyxto 100 mg film-coated tablets, Levact 2,5 mg/ml poudre pour solution à diluer pour perfusion, BGB-16673, BGB-16673, Venclyxto 10 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, MabThera 500 mg concentrate for solution for infusion, MabThera 100 mg concentrate for solution for infusion, Zydelig 150 mg film-coated tablets, Zydelig 100 mg film-coated tablets
Beone
Chronic lymphotic leukemia and Small Lymphocytic lymphoma
1 trial -
Venclyxto 100 mg film-coated tablets, MabThera 500 mg concentrate for solution for infusion, Zanubrutinib, Venclyxto 50 mg film-coated tablets
Beone
Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
1 trial -
Zanidatamab
Beone
Gastric Neoplasms
1 trial -
Zanubrutinib
Beone
B-cell malignancies
1 trial -
Zanubrutinib
Beone
B-cell Malignancies
1 trial
Drugs (3)
Search drugs →Frequently asked questions
What is Beone?
Beone (ONC) is a pharma company. headquartered in BASEL, GB. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 3 drugs, and 0 patents to this profile..
What pipeline programs does Beone sponsor?
We track 24 ClinicalTrials.gov-linked programs for Beone, including BGB-11417, BGB-11417 placebo, BGB-11417, BGB-11417, BGB-11417, Zanubrutinib and 23 more. Open each program for phase, modality, NCT IDs, and indication details.
Where does Beone company data come from?
Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.